FELIQS Corporation Clinches $9M Series A to Propel Next-Generation Treatments for ROP and AMD

FELIQS Corporation is excited to announce the successful closing of a $9 million funding round, a significant milestone that underscores the company’s innovative approach and robust vision in tackling critical unmet needs in ophthalmology and neonatology. With its roots as a dynamic Japanese startup initially funded through a seed round of $2.5 million, FELIQS is uniquely positioned to transform traditional drug discovery paradigms with its proprietary screening platform. This breakthrough technology targets lipid peroxidation and ferroptosis—a dual approach that has already demonstrated considerable efficacy in prior prospective clinical trials. The fresh capital injection will primarily drive the clinical development of two patent-protected drug candidates that target multi-billion-dollar markets. One of these candidates, FLQ-101, is a lipid peroxidation inhibitor repurposed to prevent retinopathy of prematurity (ROP), a severe condition affecting premature infants. With Phase I/II dosing planned in the U.S. for 2024, FLQ-101 represents a promising therapeutic option for a vulnerable patient population in dire need of innovation. Meanwhile, FLQ-104, a proprietary inhibitor aimed at early intervention for age-related macular degeneration (AMD), is progressing through the discovery stage in the U.S. By strategically channeling the new funding into these projects, FELIQS aims not only to advance these pioneering therapies through rigorous clinical validation but also to establish a leading foothold in these highly lucrative markets. This funding milestone is a testament to FELIQS Corporation’s commitment to transforming patient care and advancing precision medicine. The additional capital provides a solid foundation for accelerating research, fostering critical clinical collaborations, and ultimately delivering breakthrough treatments that offer hope to patients across the globe.